Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Randomized, Active-Controlled, Double-masked Trial of Intravitreal 4D-150 Gene Therapy in Adults With Diabetic Macular Edema (SPECTRA)

NCT05930561 is registered in ClinicalTrials.gov with 4D Molecular Therapeutics as lead sponsor.

NCT NCT05930561
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05930561 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Randomized, Active-Controlled, Double-masked Trial of Intravitreal 4D-150 Gene Therapy in Adults With Diabetic Macular Edema (SPECTRA)
Lead sponsor
4D Molecular Therapeutics
Phase
Phase 2
Overall status
Active, not recruiting
Start date
August 9, 2023
Completion date
February 28, 2029
Enrollment
72 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

diabetic macular edema, diabetic retinopathy